Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
British Journal of Clinical Pharmacology · 2025-02 · 91 (2) · 270-282
DOI: 10.1111/bcp.15956 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 21.12.2023. Verfasst von Elena Peruzzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano, Istituti di Ricovero e Cura a Carattere Scientifico, Aviano, Ital…. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Pharmacogenetics, Pharmacogenomic Testing. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Horizon 2020, Ministero della Salute.
Abstract (Originalsprache)
Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among adults and are more common in multimorbid patients, worsening clinical outcomes and burdening healthcare resources. Over the past decade, pharmacogenomics has been developed as a practical tool for optimizing treatment outcomes by mitigating the risk of ADRs. Some single‐gene reactive tests are already used in clinical practice, including the DPYD test for fluoropyrimidines, which demonstrates how integrating pharmacogenomic data into routine care can improve patient safety in a cost‐effective manner. The evolution from reactive single‐gene testing to comprehensive pre‐emptive genotyping panels holds great potential for refining drug prescribing practices. Several implementation projects have been conducted to test the feasibility of applying different genetic panels in clinical practice. Recently, the results of a large prospective randomized trial in Europe (the PREPARE study by Ubiquitous Pharmacogenomics consortium) have provided the first evidence that prospective application of a pre‐emptive pharmacogenomic test panel in clinical practice, in seven European healthcare systems, is feasible and yielded a 30% reduction in the risk of developing clinically relevant toxicities. Nevertheless, some important questions remain unanswered and will hopefully be addressed by future dedicated studies. These issues include the cost‐effectiveness of applying a pre‐emptive genotyping panel, the role of multiple co‐medications, the transferability of currently tested pharmacogenetic guidelines among patients of non‐European origin and the impact of rare pharmacogenetic variants that are not detected by currently used genotyping approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano, Istituti di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
- Department of Medicine, University of Udine, Udine, Italy.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Rossana Roncato, Jesse J Swen, Erika Cecchin
Förderung
- Italian Ministry of Health
- Horizon 2020
- Ministero della Salute
- Horizon 2020 Framework Programme
Zitieren
APA
Peruzzi, E., Roncato, R., De Mattia, E., Bignucolo, A., Swen, J. J., Guchelaar, H. J., Toffoli, G., & Cecchin, E. (2025). Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?. British Journal of Clinical Pharmacology, 91(2), 270-282. https://doi.org/10.1111/bcp.15956
Vancouver
Peruzzi E, Roncato R, De Mattia E, Bignucolo A, Swen JJ, Guchelaar HJ, et al. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?. British Journal of Clinical Pharmacology. 2025;91(2):270-282. doi:10.1111/bcp.15956
BibTeX
@article{Peruzzi2025,
author = {Peruzzi, Elena and Roncato, Rossana and De Mattia, Elena and Bignucolo, Alessia and Swen, Jesse J and Guchelaar, Henk-Jan and Toffoli, Giuseppe and Cecchin, Erika},
title = {Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {2},
pages = {270--282},
doi = {10.1111/bcp.15956}
}
EUVIMED